Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital

RAPID MICRO BIOSYSTEMS, INC.

Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.
Gross margin turned positive at 4% (vs -3% in Q2 2024); recurring revenue up 15% to $4.4M.
Reaffirms FY2025 revenue guidance of at least $32.0M.
Entered $45M term loan facility with Trinity Capital; $20M drawn at close, no financial covenants.
Initial interest rate 11.5% p.a.; 36-month interest-only period; warrants for 179,104 shares at $3.35/sh.

item 1.01item 2.02item 2.03item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.